Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| BPC-157 | CJC-1295 (with DAC) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection near the site of injury. | Research indicates 2 mg administered once weekly via subcutaneous injection. |
| Timing | Administer on an empty stomach or near the injury site. No strict meal timing required, though fasted state may improve absorption for oral dosing. | Evening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release. |
| Cycle Duration | Typical cycles range from 4-12 weeks depending on the injury being addressed. | 12-24 week cycles with 4-8 week breaks between cycles. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
BPC-157 is a 15-amino acid peptide derived from human gastric juice that promotes angiogenesis via dual VEGFR2-dependent (PI3K-Akt-eNOS) and VEGF-independent (Src-Caveolin-1-eNOS) nitric oxide pathways. It upregulates growth hormone receptor expression, modulates the FAK-paxillin pathway for cell migration, and counteracts damage to the nitric oxide system. Additionally, it enhances tendon fibroblast growth, promotes reticulin and collagen formation, and accelerates wound healing by mediating the NO system's protective functions.
Research indicates 250-500 mcg administered 1-2 times daily via subcutaneous injection near the site of injury.
Administer on an empty stomach or near the injury site. No strict meal timing required, though fasted state may improve absorption for oral dosing.
Typical cycles range from 4-12 weeks depending on the injury being addressed.
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid GHRH analog with four amino acid substitutions rendering it resistant to DPP-IV proteolytic inactivation. The DAC moiety covalently binds to endogenous serum albumin via a disulfide bond after injection, extending half-life to 5.8-8.1 days. It stimulates pulsatile GH release from anterior pituitary somatotrophs through GHRH receptor activation, producing dose-dependent 2-10 fold increases in plasma GH for 6+ days and 1.5-3 fold IGF-1 elevations for 9-11 days per injection.
Research indicates 2 mg administered once weekly via subcutaneous injection.
Evening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release.
12-24 week cycles with 4-8 week breaks between cycles.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →